Abstract
The isoprostanes (IsoPs) are a series of novel prostaglandin-like compounds formed in vivo in humans from the free radical-catalyzed peroxidation of arachidonate independent of the cyclooxygenase. While quantification of these compounds is a highly accurate measure of oxidant stress in vivo in humans, IsoPs also possess potent biological activity and likely mediate certain aspects of oxidative injury. The purpose of this review is to summarize selected aspects of our knowledge regarding the bioactivity of the IsoPs. I will first briefly highlight mechanisms involved in IsoP formation. Subsequently, I will discuss the biological activities of certain IsoPs that are formed in abundance in vivo and focus on two compounds, 15-F2t-IsoP and 15-E2t-IsoP, that have been studied in the greatest detail. This review will then examine, at a molecular level, mechanisms by which IsoPs exert their bioactivity. It has been shown that they are ligands for various eicosanoid receptors, in particular, the thromboxane receptor. In addition, I will discuss the controversial evidence that a unique IsoP receptor(s) exists. Finally, I will offer avenues for future research related to the development of pharmacological approaches to modulate IsoP formation and action in vivo and thus decrease the pathophysiological sequelae of oxidative injury.
Keywords: Isoprostane, peroxidation, free radical, eicosanoid, thromboxane receptor
Current Pharmaceutical Design
Title: The Isoprostanes - Unique Products of Arachidonate Peroxidation: Their Role as Mediators of Oxidant Stress
Volume: 12 Issue: 8
Author(s): Jason D. Morrow
Affiliation:
Keywords: Isoprostane, peroxidation, free radical, eicosanoid, thromboxane receptor
Abstract: The isoprostanes (IsoPs) are a series of novel prostaglandin-like compounds formed in vivo in humans from the free radical-catalyzed peroxidation of arachidonate independent of the cyclooxygenase. While quantification of these compounds is a highly accurate measure of oxidant stress in vivo in humans, IsoPs also possess potent biological activity and likely mediate certain aspects of oxidative injury. The purpose of this review is to summarize selected aspects of our knowledge regarding the bioactivity of the IsoPs. I will first briefly highlight mechanisms involved in IsoP formation. Subsequently, I will discuss the biological activities of certain IsoPs that are formed in abundance in vivo and focus on two compounds, 15-F2t-IsoP and 15-E2t-IsoP, that have been studied in the greatest detail. This review will then examine, at a molecular level, mechanisms by which IsoPs exert their bioactivity. It has been shown that they are ligands for various eicosanoid receptors, in particular, the thromboxane receptor. In addition, I will discuss the controversial evidence that a unique IsoP receptor(s) exists. Finally, I will offer avenues for future research related to the development of pharmacological approaches to modulate IsoP formation and action in vivo and thus decrease the pathophysiological sequelae of oxidative injury.
Export Options
About this article
Cite this article as:
Morrow D. Jason, The Isoprostanes - Unique Products of Arachidonate Peroxidation: Their Role as Mediators of Oxidant Stress, Current Pharmaceutical Design 2006; 12 (8) . https://dx.doi.org/10.2174/138161206776055985
DOI https://dx.doi.org/10.2174/138161206776055985 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Comparative Review of Effects of Pien Tze Huang and AnGong NiuHuang Pill and their Potential on Treatment of Central Nervous System Diseases
Mini-Reviews in Medicinal Chemistry Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials
Current Cardiology Reviews Hydrogen Sulfide and Inflammatory Joint Diseases
Current Drug Targets Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry MicroRNA Therapeutics for Cardiac Regeneration
Mini-Reviews in Medicinal Chemistry Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities
Current Neuropharmacology Caspase Function in Neuronal Death: Delineation of the Role of Caspases in Ischemia
Current Drug Targets - CNS & Neurological Disorders Curcuminoids Attenuate Myocardial Ischemia-Reperfusion Injury by Regulating Total RNA M<sup>6</sup>a Levels: <i>In Vitro</i> Study
Combinatorial Chemistry & High Throughput Screening Oxidative Stress and Opioids' Toxicity: An Update
Mini-Reviews in Organic Chemistry Saccharide Modified Pharmaceutical Nanocarriers for Targeted Drug and Gene Delivery
Current Pharmaceutical Design Derivatives of Resveratrol: Potential Agents in Prevention and Treatment of Cardiovascular Disease
Current Medicinal Chemistry Application of Hydrogen in Ophthalmology
Current Pharmaceutical Design TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology The Use of Gene Therapy Tools in Reproductive Immunology Research
Current Gene Therapy Cilostazol: Therapeutic Potential Against Focal Cerebral Ischemic Damage
Current Pharmaceutical Design RAS in the Central Nervous System: Potential Role in Neuropsychiatric Disorders
Current Medicinal Chemistry